Anti-CXCR4 antibody
| Name | Anti-CXCR4 antibody |
|---|---|
| Supplier | Abcam |
| Catalog | ab2074 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Applications | FC IHC-P IHC-F IP WB ICC/IF ICC/IF |
| Species Reactivities | Mouse, Rat, Human |
| Antigen | Synthetic peptide, corresponding to N terminal amino acids 1-14 of Human CXCR4(Peptide available as ab8126 |
| Blocking Peptide | CXCR4 peptide |
| Description | Rabbit Polyclonal |
| Gene | CXCR4 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
Anti-CXCR4 antibody (ab2074) at 1/2000 dilution + HeLa whole cell lysate
Immunocytochemistry of CXCR4 in HeLa cells with CXCR4 antibody ab2074 at 2 µg/ml.
![ab2074 at 1/100 staining differentiated rat skeletal myocytes by ICC/IF. The cells were 2% paraformaldehyde fixed for 15 minutes and then incubated cells with ab2074 overnight at 4°C. The image demonstrates CXCR4 expressing skeletal myocytes (green-cytoplasmic and cell membrane localization) with DAPI (blue-nuclear counter stain) [Right panel] and DIC (phase) image of the same skeletal myocytes ([left panel].See Abreview](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_2/3629_ab2074_3.jpg)
ab2074 at 1/100 staining differentiated rat skeletal myocytes by ICC/IF. The cells were 2% paraformaldehyde fixed for 15 minutes and then incubated cells with ab2074 overnight at 4°C. The image demonstrates CXCR4 expressing skeletal myocytes (green-cytoplasmic and cell membrane localization) with DAPI (blue-nuclear counter stain) [Right panel] and DIC (phase) image of the same skeletal myocytes ([left panel].See Abreview
ab2074 staining CXCR4 expressing cells (of mesenchymal origin) by ICC/IF. The cells were methanol fixed and blocked with BSA prior to incubation with the antibody for 1 hour. A FITC conjugated swine anti-rabbit antibody was used as the secondary. Nuclei were counterstained with DAPI.See Abreview
ab2074 staining cells from human B cell lymphoma by flow cytometry. Cells were cultured and prepared in FACS buffer. The primary antibody was diluted 1/50 and incubated with the sample for 20 minutes at 4°C. A FITC conjugated swine anti-rabbit antibody was used as the secondary.See Abreview
Lane 1 : Anti-CXCR4 antibody (ab2074) at 1/250 dilutionLane 2 : Anti-CXCR4 antibody (ab2074) at 1/500 dilutionLane 3 : Anti-CXCR4 antibody (ab2074) at 1/750 dilutionLane 4 : Anti-CXCR4 antibody (ab2074) at 1/1000 dilutionLane 5 : Anti-CXCR4 antibody (ab2074) at 1/1500 dilutionLane 6 : Anti-CXCR4 antibody (ab2074) at 1/2000 dilutionLane 1 : Lysate prepared from human Ewing`s sarcoma cellsLane 2 : Lysate prepared from human Ewing`s sarcoma cellsLane 3 : Lysate prepared from human Ewing`s sarcoma cellsLane 4 : Lysate prepared from human Ewing`s sarcoma cellsLane 5 : Lysate prepared from human Ewing`s sarcoma cellsLane 6 : Lysate prepared from human Ewing`s sarcoma cellsLysates/proteins at 500000 cells per lane.SecondaryHRP-conjugated goat polyclonal to rabbit IgG at 1/4000 dilutionPerformed under reducing conditions.
ab2074 staining CXCR4 in rat bone marrow cells by Immunocytochemistry/ Immunofluorescence. The cells were formaldehyde fixed, permeabilised in 0.1% Triton X-100 and then blocked using 5% serum for 1 hour at 25°C. Samples were then incubated with primary antibody at 1/100 for 12 hours at 4°C. The secondary antibody used was a goat anti-rabbit IgG conjugated to Alexa Fluor® 488 (green) used at a 1/250 dilution. DAPI was used to stain the cell nuclei (blue).See Abreview
ab2074 staining CXCR4 in rat kidney tubular epithelium tissue by Immunohistochemistry (Frozen sections). The tissue was formaldehyde fixed and then blocked using 2% BSA for 2 hours at 25°C. Samples were then incubated with primary antibody at 1/1000 for 9 hours at 4°C. The secondary antibody used was a goat anti-rabbit IgG conjugated to Alexa Fluor® 488 (green) used at a 1/500 dilution. DAPI was used to stain the cell nuclei (blue).See Abreview
ICC/IF image of ab2074 stained Hela cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab2074, 5µg/ml) overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti-rabbit IgG - H&L, pre-adsorbed (ab96899) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Immunofluorescence of CXCR4 in HeLa cells using ab2074 at 20 ug/ml.
Product References
Instruction of circulating endothelial progenitors in vitro towards specialized - Instruction of circulating endothelial progenitors in vitro towards specialized
Boyer-Di Ponio J, El-Ayoubi F, Glacial F, Ganeshamoorthy K, Driancourt C, Godet M, Perriere N, Guillevic O, Couraud PO, Uzan G. PLoS One. 2014 Jan 2;9(1):e84179.
CXCL12 chemokine expression suppresses human pancreatic cancer growth and - CXCL12 chemokine expression suppresses human pancreatic cancer growth and
Roy I, Zimmerman NP, Mackinnon AC, Tsai S, Evans DB, Dwinell MB. PLoS One. 2014 Mar 4;9(3):e90400.
CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and - CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and
Farkas D, Kraskauskas D, Drake JI, Alhussaini AA, Kraskauskiene V, Bogaard HJ, Cool CD, Voelkel NF, Farkas L. PLoS One. 2014 Feb 24;9(2):e89810.
The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma - The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma
Buss MC, Remke M, Lee J, Gandhi K, Schniederjan MJ, Kool M, Northcott PA, Pfister SM, Taylor MD, Castellino RC. Oncogene. 2015 Feb 26;34(9):1126-40.
The role of macrophage migration inhibitory factor in anesthetic-induced - The role of macrophage migration inhibitory factor in anesthetic-induced
Goetzenich A, Kraemer S, Rossaint R, Bleilevens C, Dollo F, Siry L, Rajabi-Alampour S, Beckers C, Soppert J, Lue H, Rex S, Bernhagen J, Stoppe C. PLoS One. 2014 Mar 25;9(3):e92827.
Silencing of CXCR4 inhibits tumor cell proliferation and neural invasion in human - Silencing of CXCR4 inhibits tumor cell proliferation and neural invasion in human
Tan XY, Chang S, Liu W, Tang HH. Gut Liver. 2014 Mar;8(2):196-204.
Gr-1+CD11b+ cells facilitate Lewis lung cancer recurrence by enhancing - Gr-1+CD11b+ cells facilitate Lewis lung cancer recurrence by enhancing
Liu T, Xie C, Ma H, Zhang S, Liang Y, Shi L, Yu D, Feng Y, Zhang T, Wu G. Sci Rep. 2014 Apr 29;4:4833.
CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated - CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated
Shen W, Hu XM, Liu YN, Han Y, Chen LP, Wang CC, Song C. J Neuroinflammation. 2014 Apr 16;11:75.
PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) - PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3)
Decker S, Finter J, Forde AJ, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray N, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu CV, Eibel H, Veelken H, Dierks C. Mol Cancer Ther. 2014 May;13(5):1231-45.
Targeting CXCR7/ACKR3 as a therapeutic strategy to promote remyelination in the - Targeting CXCR7/ACKR3 as a therapeutic strategy to promote remyelination in the
Williams JL, Patel JR, Daniels BP, Klein RS. J Exp Med. 2014 May 5;211(5):791-9.